Los investigadores trasladan su anticuerpo monoclonal a ensayos clínicos para ver si puede ser un tratamiento eficaz para el uso de metanfetamina.
COVID-19 brings challenges, learning opportunities
NIDA Virtual Career Workshop Mark your calendars! NIDA is hosting a virtual Career Workshop on November 9th, 2020 from 1:00 PM – 5:00 PM (ET) for all…
Finding from ABCD Study elucidates neural mechanisms that may underlie early weight gain
Los investigadores tienen creado un anticuerpo monoclonal destinado a interactuar con la metanfetamina y disminuir su capacidad de ingresar al cerebro…
People with SUDs may be particularly vulnerable to COVID-19 and its most adverse health outcomes
A PROJECT OF:
This program is funded wholly, or in part, by the Government of the District of Columbia, DC Health, HIV/AIDS, Hepatitis, STD, TB Administration (HAHSTA).